Moreover, the discovery that increased mitochondrial metabolism contributes to the resistance of AML cells to IDH inhibitors [124] could in the future pave the way for the development of innovative therapies based on the combination of IDH inhibitors with drugs that impair mitochondrial respiration, such as the antidiabetic metformin [126]. Here, IDH2 is linked to acute myeloid leukemia.